He is zooming in on topical preparations

According to Zelmic CEO David Sagna, topical products in drug development is a growing market, and to keep pace with the development, the company is awaiting approval for its new...

Bio-Works

Astra Zeneca's Covid-19 vaccine Vaxzevria is being withdrawn worldwide

AstraZeneca initiates a worldwide withdrawal of its Covid vaccine Vaxzevria. The measure is taken just months after the company admitted the vaccine can cause a...

Swedish breakthrough in Alzheimer’s: “We can finally present great data”

Treatments for Alzheimer’s disease are currently among the hottest topics in drug development. Two Swedish research companies with high ambitions and successes ...

New report: Fewer PhDs in life sciences

A new report from Vinnova suggests that competency returns in the life science sector are declining.

The key to successful collaboration between industry and academia

Why is collaboration between industry and academia necessary in the life sciences sector? What obstacles exist, and what is the key to successful collaboration?

On the hunt for high throughput diagnostics

Global diagnostics companies and laboratories are in a race against time to adapt testing capacity to current demand. Due to the global COVID 19 pandemic, the d...

Quality solutions for medical device R&D applications

From R&D to the quality assurance of series production in medical device manufacturing.

Tyska Biontech storsatsar i Storbritannien

Den tyska vaccin- och läkemedelsutvecklaren Biontech ska investera upp till en miljard pund, motsvarande nästan 13 miljarder kronor, på att utveckla sin forskni...

Roches alzheimerprogram vidare till fas III efter positiva data

Roche rapporterar positiva preliminära data från sitt alzheimerprojekt trontinemab, och ska nu gå vidare med en fas III-studie.

The Swedish Life Science Office: “We lost in both coordination and manpower”

Since the turn of the year, the Swedish government’s life science office has operated at a lower capacity. Life Science Sweden has spoken to Pontus Holm, Depart...

Rickard Sandberg on this year’s Nobel Prize in Medicine: ”A key discovery”

The discovery that paved the way for the development of todays mRNA vaccines is the basis for this year’s Nobel Prize in Physiology or Medicine.

Marie Gårdmark: Potential step change – EU regulators get to play with data

A new pilot from EMA is starting in September to assess wether the analysis of 'raw data' by regulatory authorities improves the evaluation of marketing approval for new medicines. Marie Grådmark writes in a column that she is looking forward...

Final assembly inspection of medical plastics

Technical paper by ZEISS Medical Industry Solutions.

Meeting with focus on South Korea and Japan’s life sciences

Large, complex and exciting – this is how Britta Stenson, Business Sweden, describes the life science markets of Japan and South Korea, which took centre stage ...

Novo Nordisk to invest billions in new quality control lab

Novo Nordisk has announced plans to invest 2.9 billion Danish kroner in order to establish a new quality control laboratory in Hillerød in northern Zealand, Denmark.

USA lämnar Världshälsoorganisationen

USA:s nyinstallerade president Donald Trump har lagt en presidentorder på att USA ska lämna Världshälsoorganisationen, WHO.

”Bilder är det perfekta målet för AI”

Allt fler lösningar baserade på artificiell intelligens utvecklas och används i vården. Radiologi är ett område som lämpar sig väl för tekniken. Det menar Sophi...

New features in ZEISS CALYPSO 2024

ZEISS CALYPSO is your universal software for dimensional metrology applications.

Bayer has cut 1,500 roles – so far

German chemical and pharmaceutical group Bayer cut more than 1,500 roles in the first quarter alone– and most of them were management positions.

Introduction of ZEISS Imaging Systems for Super-Resolution

Webinar recording about the ZEISS Lattice SIM technology.

Ready-to-install solutions for the lab-on-a-chip

Design for manufacturing lab-on-a-chip devices Reducing time-to-market together

Bioarctic i miljardavtal med läkemedelsjätte

Det svenska alzheimerbolaget Bioarctic licensierar ut kommersialisering och utveckling av två antikroppar till den globala läkemedelsjätten Bristol Myers Squibb.

Samuel Lagercrantz: ”Geoffrey Hintons farhågor”

”Ska vi få en så ljus framtid som möjligt där AI används på bästa sätt behövs både de som ser risker med den nya tekniken och de som ser sig som teknikoptimiste...